Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SCYX
SCYX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SCYX News
SCYNEXIS Announces 1-for-8 Reverse Stock Split
May 22 2026
seekingalpha
SCYNEXIS Announces Reverse Stock Split Plan
May 22 2026
Newsfilter
SCYNEXIS Completes Acquisition of SCY-770 for ADPKD Treatment
May 11 2026
Newsfilter
SCYNEXIS Approves Inducement Equity Awards for New VP
May 07 2026
Newsfilter
U.S. March Manufacturing PMI Slightly Rises
Apr 01 2026
seekingalpha
SCYNEXIS Secures $40M in Securities Purchase Agreement
Mar 31 2026
seekingalpha
Scynexis Acquires Kidney Disease Treatment, Shares Surge
Mar 31 2026
stocktwits
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
Mar 31 2026
NASDAQ.COM
Poxel Enters Drug Agreement with SCYNEXIS for PXL770
Mar 31 2026
Newsfilter
SCYNEXIS Reports 2025 Financial Highlights and Pipeline Progress
Mar 05 2026
NASDAQ.COM
SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity
Jan 21 2026
Yahoo Finance
Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections
Nov 17 2025
Newsfilter
SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update
Nov 05 2025
Newsfilter
Guggenheim Reiterates Buy Rating on SCYNEXIS, Adjusts Price Target to $3
Oct 28 2025
Benzinga
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
SCYNEXIS Announces Encouraging Phase 1 Findings for Antifungal Candidate SCY-247
Sep 30 2025
NASDAQ.COM
Show More News
